CA19-9

CA19‑9 is a tumor‑associated antigen measured in a blood specimen to provide a numeric value that may support assessment of pancreatic and other gastrointestinal conditions. The test requires a standard venous blood draw, and the laboratory quantifies the CA19‑9 concentration using a validated immunoassay. Results are typically returned within a few business days, allowing clinicians to track changes over time. At a cost of $200, the service includes the sample collection, laboratory analysis of the CA19‑9 marker, and a detailed electronic report that can be reviewed with a healthcare provider. This panel is especially relevant for adults being investigated for pancreatic disease, biliary obstruction, or monitoring known conditions where CA19‑9 trends are clinically informative.